CA2763130C - Inhibiteurs de pde10 radio-marques - Google Patents
Inhibiteurs de pde10 radio-marques Download PDFInfo
- Publication number
- CA2763130C CA2763130C CA2763130A CA2763130A CA2763130C CA 2763130 C CA2763130 C CA 2763130C CA 2763130 A CA2763130 A CA 2763130A CA 2763130 A CA2763130 A CA 2763130A CA 2763130 C CA2763130 C CA 2763130C
- Authority
- CA
- Canada
- Prior art keywords
- pde10
- compound
- aryl
- heteroaryl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention porte sur des composés radio-marqués de pyrimidinone de formule structurelle générale I, qui sont utiles en tant que radio-traceurs pour une imagerie quantitative de PDE10 chez les animaux.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18214909P | 2009-05-29 | 2009-05-29 | |
US61/182,149 | 2009-05-29 | ||
PCT/US2010/036186 WO2010138577A1 (fr) | 2009-05-29 | 2010-05-26 | Inhibiteurs de pde10 radio-marqués |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2763130A1 CA2763130A1 (fr) | 2010-12-02 |
CA2763130C true CA2763130C (fr) | 2017-01-17 |
Family
ID=43223044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2763130A Active CA2763130C (fr) | 2009-05-29 | 2010-05-26 | Inhibiteurs de pde10 radio-marques |
Country Status (7)
Country | Link |
---|---|
US (1) | US8846000B2 (fr) |
EP (1) | EP2435048B1 (fr) |
JP (1) | JP5718323B2 (fr) |
AU (1) | AU2010254149B2 (fr) |
CA (1) | CA2763130C (fr) |
ES (1) | ES2739973T3 (fr) |
WO (1) | WO2010138577A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2467382B1 (fr) | 2009-08-17 | 2014-06-25 | Merck Sharp & Dohme Corp. | Amino-tétrahydro-pyridopyrimidine inhibiteurs de pde10 |
JP2014510055A (ja) | 2011-02-18 | 2014-04-24 | アラーガン インコーポレイテッド | ホスホジエステラーゼ10(pde10a)阻害剤としての置換6,7−ジアルコキシ−3−イソキノリノール誘導体 |
CA2846122C (fr) * | 2011-08-22 | 2019-06-11 | Takeda Pharmaceutical Company Limited | Composes radiomarques et leur utilisation en tant que radiotraceurs pour l'imagerie quantitative de la phosphodiesterase (pde10a) chez les mammiferes |
WO2014071044A1 (fr) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a) |
EP2951176A1 (fr) * | 2013-01-31 | 2015-12-09 | F. Hoffmann-La Roche AG | Composés radiomarqués |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
USD977386S1 (en) | 2020-09-22 | 2023-02-07 | Positec Power Tools (Suzhou) Co., Ltd. | Battery pack |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6380204B1 (en) * | 1997-02-28 | 2002-04-30 | Pfizer Inc | Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for the treatment of neurodegenerative and CNS-trauma related conditions |
US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
US20050202550A1 (en) * | 2004-03-12 | 2005-09-15 | Pfizer Inc | Crystal structure of 3', 5'-cyclic nucleotide phosphodiesterase (PDE10A) and uses thereof |
WO2008020302A2 (fr) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Composés hétéro-aromatiques à base de quinoline |
KR100933559B1 (ko) * | 2007-10-01 | 2009-12-23 | 재단법인서울대학교산학협력재단 | 3H-퀴나졸린-4-온 유도체를 함유하는 Hsp90 억제제및 이를 이용한 항암제 |
AU2010229968A1 (en) * | 2009-03-24 | 2011-10-13 | Gilead Calistoga Llc | Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
-
2010
- 2010-05-26 ES ES10781130T patent/ES2739973T3/es active Active
- 2010-05-26 AU AU2010254149A patent/AU2010254149B2/en active Active
- 2010-05-26 US US13/320,816 patent/US8846000B2/en active Active
- 2010-05-26 EP EP10781130.9A patent/EP2435048B1/fr active Active
- 2010-05-26 CA CA2763130A patent/CA2763130C/fr active Active
- 2010-05-26 JP JP2012513203A patent/JP5718323B2/ja active Active
- 2010-05-26 WO PCT/US2010/036186 patent/WO2010138577A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU2010254149A1 (en) | 2011-12-22 |
ES2739973T3 (es) | 2020-02-05 |
CA2763130A1 (fr) | 2010-12-02 |
AU2010254149B2 (en) | 2014-08-21 |
US20120064005A1 (en) | 2012-03-15 |
EP2435048A4 (fr) | 2013-07-10 |
JP5718323B2 (ja) | 2015-05-13 |
US8846000B2 (en) | 2014-09-30 |
EP2435048A1 (fr) | 2012-04-04 |
WO2010138577A1 (fr) | 2010-12-02 |
EP2435048B1 (fr) | 2019-07-03 |
JP2012528176A (ja) | 2012-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2763130C (fr) | Inhibiteurs de pde10 radio-marques | |
US9266881B2 (en) | Triazolopyridinone PDE10 inhibitors | |
US10370336B2 (en) | Phenyl-cyanoquinolinone PDE9 inhibitors | |
WO2017019723A1 (fr) | Aza-cyanoquinolinone utiles en tant qu'inhibiteurs de pde9 | |
EP2621276B1 (fr) | 2-alcoxy pyrimidine inhibiteur de pde10 | |
US20130203756A1 (en) | Isoindoline pde10 inhibitors | |
WO2010138585A1 (fr) | Pyrimidinones constituant des inhibiteurs de pde10 | |
US9284302B2 (en) | Cyclobutyl benzimidazoles as PDE 10 inhibitors | |
EP2922543A1 (fr) | Dérivés de pyridone substitués utilisés en tant qu'inhibiteurs de pde10 | |
US20110319409A1 (en) | 7-aza-quinazoline pde10 inhibitors | |
EP2919782B1 (fr) | Triazoles substitués par un alcool secondaire en tant qu'inhibiteurs de pde10 | |
EP2968324B1 (fr) | Dérivés de pyridazinone substitués en tant qu'inhibiteurs de pde10 | |
WO2014078214A1 (fr) | Azétidine benzimidazoles utilisables en tant qu'inhibiteurs de pde10 | |
US9359348B2 (en) | Cyclopropyl imidazopyridine PDE10 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20150525 |